Kodiak Sciences Q1 net loss narrows as R&D rises

Kodiak Sciences

07/05/2026 21:08

Overview

Retina-focused biotech reported Q1 net loss narrowed yr/yr to $58.2 mln, or $0.94 per share

R&D expenses rose due to increased clinical activity in late-stage studies

Outlook

Company expects DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in September 2026

Topline results from PEAK Phase 3 study for KSI-101 expected in 4Q 2026

Kodiak expects current cash to support operations into 2027

Result Drivers

HIGHER R&D SPENDING - Increased clinical activities in PEAK/PINNACLE and DAYBREAK studies drove higher R&D expenses

LOWER G&A EXPENSES - G&A expenses fell yr/yr, partly offset by sublease income from a corporate office building

Company press release: ID:nPn9mLhf7a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.94
Q1 Net Income
-$58.16 mln
Q1 Basic EPS
-$0.94
Q1 Operating Expenses
$59.78 mln
Q1 Operating Income
-$59.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kodiak Sciences Inc is $58.00, about 26.4% above its May 6 closing price of $45.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)